CoChat

Cevimeline

Weber, Juliane, Keating, Gillian M · 2008 · Drugs

The DOI matches its Crossref record; 25 of the 25 references it cites were found in a registry or an index.

Abstract

Cevimeline is an orally administered muscarinic receptor agonist that is indicated for the treatment of symptoms of dry mouth in patients with Sjogren's syndrome. Several well designed placebo-controlled trials demonstrated that 4-12 weeks' therapy with cevimeline 30 mg three times daily improved symptoms of dry mouth in patients with Sjogren's syndrome. Other symptoms, such as dry eye symptoms and overall dryness, also improved to a significantly greater extent with cevimeline than with placebo. Moreover, cevimeline significantly improved the salivary flow rate in patients with Sjogren's syndrome. Increased salivary flow was maintained in the longer term with cevimeline in patients with Sjogren's syndrome and symptoms of dry mouth, according to the results of an open-label 52-week study. From week 20 onwards, rates of patient and investigator satisfaction with the cevimeline dosage were > or =88%. Oral cevimeline 30 mg three times daily was generally well tolerated in patients with Sjogren's syndrome, with many of the most commonly reported adverse events reflecting the pharmacological action of the drug.

Overview

Integrity signals

Registry

Crossref · 10.2165/00003495-200868120-00006

Cites

25 of 25 references verified0 citation errors · 0 not checkable

Statistics

Recomputing p-values needs the paper’s full text.

Verification

Claims the paper makes

This paper’s full text isn’t openly available, so its claims and self-check weren’t run. The registry and citation checks still apply.

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

Citations

Cites

Show all 25 references

Research works printed but not linked: 5

  1. Ohtani, 1990, Rinsho Iyaku, 6, 1551
  2. Kashiwazaki, 2001, Shinryo To Shinyaku, 38, 393
  3. Kashiwazaki, 2001, Shinryo To Shinyaku, 38, 333
  4. Ichikawa, 2001, Shinryo To Shinyaku, 38, 349
  5. Ichikawa, 2001, Shinryo To Shinyaku, 38, 369

Cited by

See all 33

Metadata

Authors
Weber, J., & Keating, G. M.
Affiliations
Wolters Kluwer Health (NZ)
Corresponding author
Keating, Gillian M
Venue
Drugs
Published
2008
Volume
68
Issue
12
Pages
1691-1698
ISSN
0012-6667 (ISSN-L)
OpenAlex
W3192301371
Cited by
33
References
25
Citations by year
2025: 2 · 2024: 4 · 2023: 3 · 2022: 2 · 2021: 3 · 2020: 2 · 2019: 1 · 2018: 1 · 2016: 1 · 2015: 3 · 2014: 1 · 2013: 1 · 2012: 1
FWCI
1.81
Type
journal article
Language
en
Open access
closed
Locations
  • Drugs (publishedVersion)
  • PubMed (publishedVersion)
Topics
  • Health Sciences › Medicine › Physiology (medical) › Salivary Gland Disorders and Functions
  • Health Sciences › Medicine › Ophthalmology › Ocular Surface and Contact Lens
  • Health Sciences › Dentistry › General Dentistry › HIV/AIDS oral health manifestations
Keywords
cevimeline, Sjögren's syndrome, xerostomia, muscarinic agonists, salivary flow rate, dry eye symptoms, drug tolerability, adverse events, patient satisfaction
MeSH terms
Animals, Diarrhea, Female, Half-Life, Humans, Nausea, Quinuclidines, Rhinitis, Sjogren's Syndrome, Sweating, Thiophenes, Molecular Structure, Randomized Controlled Trials as Topic, Treatment Outcome, Muscarinic Agonists, Area Under Curve

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

How to cite

Cite CoChat for the checks on this page, and the paper for its own findings.

This page
CoChat. (2026). Citation check: Cevimeline. https://app.cochat.ai/papers/10.2165/00003495-200868120-00006
The paper
Weber, J., & Keating, G. M. (2008). Cevimeline. Drugs. https://doi.org/10.2165/00003495-200868120-00006

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.